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Objectives Our purpose was to clarify the clinical utility of identifying metabolic syndrome (MetS) in patients with coronary
artery disease (CAD).
Background It is uncertain whether MetS influences prognosis in patients with CAD and whether the risk associated with
MetS exceeds the risk associated with the sum of its individual components.
Methods In a post hoc analysis, we compared the incidence of death or myocardial infarction (MI) in stable CAD patients in the
COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial according to the pres-
ence () or absence () of MetS and diabetes: Group A, MetS/diabetes; Group B, MetS/diabetes; Group C,
MetS/diabetes; and Group D, MetS/diabetes. We explored which MetS components best predicted adverse
outcomes and whether MetS had independent prognostic significance beyond its individual components.
Results Of 2,248 patients, 61% had MetS and 34% diabetes. Risk for death or MI increased from Group A (14%) to Group D
(25%, p  0.001). Hypertension (hazard ratio [HR]: 1.30; 95% confidence interval [CI]: 0.98 to 1.71; p  0.07), low
high-density lipoprotein cholesterol (HR: 1.26; 95% CI: 1.03 to 1.55; p  0.03), and elevated glucose (HR: 1.17; 95%
CI: 0.96 to 1.47; p  0.11) most strongly predicted death or MI. MetS was associated with an increased risk of death
or MI (unadjusted HR: 1.41; 95% CI: 1.15 to 1.73; p  0.001). However, after adjusting for its individual components,
MetS was no longer significantly associated with outcome (HR: 1.15; 95% CI: 0.79 to 1.68; p 0.46). Allocation to initial
percutaneous coronary intervention did not affect the incidence of death or MI within any group.
Conclusions Among stable CAD patients in the COURAGE trial, the presence of MetS identified increased risk for death or MI,
but MetS did not have independent prognostic significance after adjusting for its constituent components. The
addition of early percutaneous coronary intervention to optimal medical therapy did not significantly reduce the
risk of death or MI regardless of MetS or diabetes status. (Clinical Outcomes Utilizing Revascularization and Ag-
gressive Drug Evaluation [COURAGE]; NCT00007657) (J Am Coll Cardiol 2011;58:131–7) © 2011 by the
American College of Cardiology Foundation
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Metabolic Syndrome and Diabetes in the COURAGE Trial July 5, 2011:131–7The metabolic syndrome (MetS), a
constellation of metabolic risk
factors for coronary artery disease
(CAD) tightly linked to abdom-
inal obesity and insulin resis-
tance, is believed to increase the
risk for developing type 2 diabe-
tes and CAD (1–4). The Na-
tional Cholesterol Education
Program (NCEP) proposed de-
tection of MetS as a method to
identify patients at increased risk
for CAD and as a potential sec-
ondary target of therapy (5).
However, the clinical utility of
the syndrome was criticized in a
joint statement of the American
Diabetes Association and the
European Association for the
Study of Diabetes (6). Specifi-
cally, the authors stated that “pa-
tients with diabetes or clinical cardiovascular disease should
be excluded from the case definition of metabolic syndrome,
See page 138
as they provide no additional understanding of risk or
treatment recommendations that are otherwise not currently
recommended.” Accordingly, we performed a post hoc
analysis of the COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation) trial to
determine whether there is: 1) a continuum of risk
associated with MetS and diabetes among CAD patients;
2) improved risk stratification by identifying MetS, even
after adjusting for its individual components; and 3) a
significant reduction in the risk death or myocardial infarc-
tion (MI) by the addition of percutaneous coronary inter-
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Abbreviations
and Acronyms
BMI  body mass index
CAD  coronary artery
disease
CI  confidence interval
HDL  high-density
lipoprotein
HR  hazard ratio
MetS  metabolic
syndrome
MI  myocardial infarction
NCEP  National
Cholesterol Education
Program
OMT  optimal medical
therapy
PCI  percutaneous
coronary interventionManuscript received December 27, 2010; revised manuscript received February 3,
2011, accepted February 22, 2011.vention (PCI) to optimal medical therapy (OMT) in
COURAGE patients with MetS.
Methods
The methods and results of the COURAGE trial (clinical
trial number NCT00007657) have been reported previously
(7,8). The study protocol was approved by the human rights
committee at the coordinating center and by local institu-
tional review boards. Written informed consent was ob-
tained from all patients. An independent data and safety
monitoring board controlled the trial. Data management
and analyses were performed solely by the data coordinating
centers and overseen by the trial’s executive committee,
which had full access to the data and analyses and vouches
for its accuracy and completeness.
Diabetes was defined as a patient-reported history of
diabetes or fasting blood glucose 125 mg/dl. MetS was
defined by the presence of 3 or more of the following
baseline patient characteristics, based upon the NCEP
definition (1): 1) body mass index (BMI) 30 kg/m2;
) fasting triglycerides 150 mg/dl; 3) high-density lipo-
rotein (HDL) cholesterol 40 mg/dl in men or 50
g/dl in women; 4) systolic blood pressure 130 mm Hg,
iastolic blood pressure 85 mm Hg, or taking hydrochlo-
othiazide; and 5) fasting glucose 100 mg/dl or the
resence of diabetes. As validated by other investigators
9,10), BMI was used as the measure for obesity because
aist circumference was not measured. Patients were clas-
ified according to the presence () or absence () of MetS
nd diabetes: Group A, MetS/diabetes; Group B,
MetS/diabetes; Group C, MetS/diabetes; and
Group D, MetS/diabetes. The median duration of
follow-up was 4.6 years (range 2.5 to 7.0 years).
Statistical analysis. This was a post hoc analysis. Patient
characteristics across groups were assessed by analysis of
variance for continuous variables and the chi-square test for
discrete variables. The Cochran-Armitage test was used for
trend. Estimates of the cumulative event rate were calcu-
lated by the Kaplan-Meier method. Time-to-endpoint
analyses were done using Cox regression or stepwise Cox
regression. Cox regression was also used for the adjusted
analyses. The rate of death or MI across subsets or treat-
ment groups was assessed by the chi-square test.
Results
Baseline characteristics. The baseline characteristics of
patients according to the presence or absence of MetS and
diabetes are summarized in Table 1. Of the 2,248 patients
in the COURAGE trial with complete baseline data col-
lected (from a total of 2,287 enrolled), 61% fulfilled the
NCEP criteria of MetS. Roughly one-third had no MetS or
diabetes, one-third had MetS without diabetes, and one-
third had diabetes. Approximately 85% of patients with
diabetes had MetS. Apart from the components of MetS,
the groups differed substantially by age, sex, and race.
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July 5, 2011:131–7 Metabolic Syndrome and Diabetes in the COURAGE TrialPatients with diabetes were less likely to be current smokers
and had lower low-density lipoprotein cholesterol. A greater
proportion of patients with diabetes had a history of heart
failure and lower ejection fraction.
Risk associated with MetS and diabetes. In this popula-
tion of patients with CAD, Cox regression analysis showed
that MetS was associated with increased risk, as compared
Figure 1 Cumulative Rate of Death or MI by MetS/Diabetes Su
Cumulative rate of death or myocardial infarction (MI) by metabolic syndrome (Met
DM  diabetes absent; DM  diabetes present; MetS  metabolic syndrom
Baseline Characteristics by MetS/DM SubsetTable 1 Baseline Characteristics by MetS/DM Subset
Group A
MetS/DM
(n  765)

Age, yrs 62.9 10.1 6
Male 83.9%
White 90.3%
Hypertension 48.8%
Smoker 29.5%
LDL cholesterol, mg/dl 106.3 33.7 10
HDL cholesterol, mg/dl 46.6 12.4 3
Triglycerides, mg/dl 129.4 69.1 20
Systolic blood pressure, mm Hg 128.7 20.2 13
Diastolic blood pressure, mm Hg 73.2 11.1 7
Body mass index, kg/m2 26.7 3.6 3
Prior myocardial infarction 39.6%
Prior percutaneous coronary intervention 13.0%
Prior coronary bypass graft surgery 8.5%
History of heart failure 21 (5%)
0/1-vessel disease 325 (42%)
2-vessel disease 291 (38%)
3-vessel disease 147 (19%)
Ejection fraction, % 61.4 10.2 6
Values are mean  SD or %. The number of patients for some of the variables in this table varies
DM  diabetes mellitus; HDL  high-density lipoprotein; LDL  low-density lipoprotein; MetS with the absence of MetS for each of the following
endpoints: death or MI: hazard ratio (HR): 1.41 (95%
confidence interval [CI]: 1.15 to 1.73), p  0.001; death:
R: 1.49 (95% CI: 1.09 to 2.05), p  0.01; MI: HR: 1.41
95% CI: 1.10 to 1.82), p  0.008; and heart failure: HR:
.96 (95% CI: 1.72 to 5.10), p  0.001. When diabetes was
dded to the Cox regression model, MetS remained a
set during a median follow-up of 4.6 years (range 2.5 to 7.0 years).
ent; MetS  metabolic syndrome present.
B
DM
17)
Group C
MetS/DM
(n  121)
Group D
MetS/DM
(n  645) p Value
10.0 64.4 11.0 62.0 9.1 0.001
% 93.4% 84.5% 0.05
% 80.2% 79.4% 0.001
% 52.1% 84.8% 0.001
% 22.3% 23.8% 0.002
34.6 102.2 30.1 100.3 33.3 0.001
8.5 48.7 10.9 37.8 10.2 0.001
107.6 104.0 39.2 202.3 116.3 0.001
18.2 125.9 20.1 136.8 19.1 0.001
11.3 70.1 11.1 74.7 11.1 0.001
4.7 26.5 3.0 32.0 5.2 0.001
% 32.2% 37.7% 0.37
% 14.1% 18.5% 0.02
% 11.6% 13.3% 0.04
%) 6 (7%) 53 (12%) 0.001
8%) 46 (38%) 210 (33%) 0.02
9%) 43 (36%) 260 (40%)
3%) 32 (26%) 173 (27%)
10.6 59.1 10.7 59.9 11.3 0.05
y due to missing data.
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Metabolic Syndrome and Diabetes in the COURAGE Trial July 5, 2011:131–7significant predictor of death or MI (HR: 1.27 [95% CI:
1.00 to 1.60], p  0.05).
Figure 1 shows the cumulative rate of death or MI by
etS subset during the trial. The rate of death or MI
uring long-term follow-up in patients with MetS and
iabetes was 25% compared with 14% in patients with
either MetS nor diabetes. The rates among patients with
etS and no diabetes (16%) and diabetes with no MetS
17%) were intermediate. Figure 2 shows the time to death
r MI by MetS subset.
isk associated with number and combination of MetS
omponents. Table 2 presents the distribution of the
number of components of MetS and their relationship to
endpoint events. For each endpoint, there was a significant
trend for increasing risk as the number of MetS components
increased. This was particularly true for patients with
multivessel disease as compared with single-vessel disease.
We performed a stepwise regression of MetS components
Figure 2 Kaplan-Meier Estimates of Time to Death or MI
by MetS/Diabetes Subset
Kaplan-Meier estimates of time to death or MI by MetS subset during a median
follow-up of 4.6 years (range 2.5 to 7.0 years). Abbreviations as in Figure 1.
Distribution of the Number of Components of MetS and EventsTable 2 Distribution of the Number of Components of MetS and
Events
Number
0 1 2
n  72 (3) n  290 (13) n  545 (24)
Death /MI 10 (14) 44 (15) 81 (15)
Death 7 (10) 16 (6) 32 (6)
MI 4 (6) 33 (11) 52 (10)
HF 1 (1) 8 (3) 7 (1)
PCI/CABG 13 (18) 57 (20) 129 (24)Value are n (%).
CABG  coronary artery bypass graft surgery; HF  heart failure; MetS  metabolic syndrome; MI  mto determine which of the components were most strongly
related to adverse outcomes (Table 3). Of the 5 individual
components of MetS, those most predictive of the compos-
ite endpoint were hypertension, low HDL cholesterol, and
elevated glucose; however, each component was predictive
of at least 1 of the endpoints.
To test whether the prognostic significance of MetS
exceeded the risk associated with the sum of its individual
components, we adjusted for the individual components of
the syndrome and found that MetS was no longer an
independent predictor of death or MI (HR: 1.15; 95% CI:
0.79 to 1.68; p  0.46). Similarly, MetS was not an
independent predictor of death alone or MI alone after
adjusting for the 5 individual components, suggesting that
there is no additional prognostic importance of MetS over
and above the individual risk factors from which it is
comprised.
Impact of PCI on events according to MetS/diabetes
subset. Rates of death or MI by MetS subset and treatment
group are summarized in Table 4. Within each subset,
allocation to initial PCI did not significantly influence the
incidence of death or MI.
Discussion
In the COURAGE trial, we noted a continuum of risk
associated with MetS and diabetes among patients with
stable CAD. Those with neither MetS nor diabetes were at
lowest risk for MI or death, and those with both MetS and
diabetes were at highest risk. Approximately 60% of this
CAD population had MetS, and approximately one-half of
MetS patients had diabetes. The vast majority of patients
with diabetes had MetS, whereas the small subset of
patients with diabetes and no MetS was at lower risk for
death or MI than patients with both diabetes and MetS. We
delivered aggressive medical therapy in the COURAGE trial for
each of the risk factors that comprise MetS, but we failed to
lower BMI (11), potentially the root cause of the metabolic
derangements of MetS. Despite OMT, MetS conferred a
worse prognosis, with a hazard ratio of 1.4 for the
composite endpoint of death or MI, 1.5 for all-cause death,
and 1.4 for MI. However, after adjusting for its individual
nts
ponents
p Value
for
Trend
3 4 5
n  621 (27) n  502 (22) n  255 (11)
126 (20) 92 (18) 63 (25) 0.001
57 (9) 41 (8) 27 (11) 0.03
79 (13) 62 (12) 44 (17) 0.002
28 (5) 23 (5) 20 (8) 0.001
170 (27) 134 (27) 76 (30) 0.001Eve
of Comyocardial infarction; PCI  percutaneous coronary intervention.
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July 5, 2011:131–7 Metabolic Syndrome and Diabetes in the COURAGE Trialcomponents, MetS had no independent prognostic signifi-
cance for the endpoints we measured.
As would be expected from the Framingham Risk Score,
patients with all 5 components of MetS were at higher risk
than patients with fewer components. This has been ob-
served in other studies of MetS (12). In our sample
population, the most consistent predictors of developing an
adverse outcome were low HDL cholesterol and hypergly-
cemia (or diabetes), although each component contributed
to at least 1 of the endpoints we studied. Different investi-
gators have found different MetS components to be associ-
ated with higher risk of future adverse events, especially
elevated glucose (13–19) and elevated blood pressure
(12–15,17), with risk estimates usually falling within the
95% confidence limits of our findings.
A joint statement of the American Diabetes Association
and the European Association for the Study of Diabetes (6)
argued that identification of MetS provided no additional
information about risk and did not change management,
particularly among patients with established CAD or dia-
betes. Stern et al. (20) found that among patients with
cardiovascular disease, the excess risk for all-cause and
cardiovascular disease mortality associated with MetS was
driven primarily by including diabetes in the definition; and
after controlling for diabetes, the presence of MetS no
longer conferred excess risk. This is in contrast with our
findings and those of other investigators who found an
incremental impact of MetS on prognosis of patients with
established CAD independent of diabetes (21,22).
A critical gap in the literature on MetS is the need to
determine whether the prognostic significance of this syn-
drome is greater than the risk conferred by the sum of its
component risk factors (6). We found that MetS did not
confer independent risk greater than the risk of its individ-
ual components. Our findings support the observations of
other investigators who found no independent effect from
MetS on cardiovascular risk above and beyond the impact of
individual risk factor components (3,23–25).
The potential clinical value of MetS is that it identifies
patients with a worse prognosis than can be identified by
established risk factors and/or who require therapy that is
different from established treatment guidelines. Our finding
that the increased risk of MetS patients is accounted for
Stepwise Cox Regression of MetS ComponentsTable 3 Stepwise Cox Regression of MetS C
Event High Glucose/DM Low HDL
Death/MI 1.17 (0.96–1.47) 1.26 (1.03–1.55)
Death 1.46 (1.05–2.02)
MI 1.21 (0.93–1.56) 1.34 (1.04–1.74)
HF 2.75 (1.54–4.91) 1.63 (1.02–2.61)
PCI/CABG 1.16 (0.97–1.39)
Values are hazard ratios (95% confidence intervals).
Abbreviations as in Tables 1 and 2.principally by the risk factors that define its presence msuggests minimal incremental value from grouping these
risks into a distinct diagnosis or syndrome, and indicates
that the underlying risk factors should be the principal
targets of therapy. However, the blood pressure and glucose
thresholds used to define MetS are lower than guideline-
recommended thresholds for pharmacological treatment of
these risk factors (5,26,27), and there are no thresholds for
pharmacological treatment aimed directly at raising HDL
cholesterol and lowering triglycerides. Therefore, it is pos-
sible that the identification of MetS may help physicians
recognize patients at increased risk who may not be recog-
nized as such by current guidelines. This hypothesis was not
tested in our study. Perhaps the most practical impact of this
interpretation is that identification of MetS in patients not
meeting established treatment criteria for lipids, glucose, or
blood pressure should trigger intensive lifestyle counseling
focused on physical activity, diet, and weight loss.
Although the presence of MetS and diabetes increased
the risk of adverse events in our study, randomization of
patients with MetS and/or diabetes to initial PCI did not
reduce the incidence of death or MI. This is consistent with
the main results of the COURAGE trial.
Study limitations. First, this is a post hoc analysis, and
subject to the inherent flaws of such analyses (28). Second,
there are many different proposed definitions of MetS, and
we used only the revised 2004 NCEP definition (1). The
principal difference between that definition and the 2001
NCEP definition of MetS (5) is that the criterion for fasting
hyperglycemia changed from 110 to 100 mg/dl. How-
ver, a recent systematic review of 87 studies involving
51,083 patients found that there was little variation in
ardiovascular risk between the revised NCEP definition
utcomeonents by Outcome
mponent
Triglycerides Hypertension Obesity
1.30 (0.98–1.71)
(0.94–1.55)
1.54 (0.99–2.38)
(0.98–1.37) 1.22 (0.97–1.55)
Rates of Death or MI by MetS/DM Subsetand Treatment G oupTable 4 Rates of Death or MI by MetS/DM Subsetand Treatment Group
MetS/DM
Subset
Percutaneous Coronary
Intervention  Optimal
Medical Therapy
Optimal Medical
Therapy p Value
MetS/DM 60/391 (15%) 49/374 (13%) 0.37
MetS/DM 65/368 (18%) 52/349 (15%) 0.32
MetS/DM 10/62 (16%) 10/59 (17%) 0.90
MetS/DM 75/305 (25%) 86/340 (25%) 0.84by Oomp
Co
High
1.21
1.57DM diabetes absent;DM diabetes present;MetSmetabolic syndrome absent;MetS
etabolic syndrome present.
136 Maron et al. JACC Vol. 58, No. 2, 2011
Metabolic Syndrome and Diabetes in the COURAGE Trial July 5, 2011:131–7compared with the original NCEP definition (4), and others
have shown high levels of consistency among different
definitions of MetS and important cardiovascular outcomes
(18). Furthermore, we substituted BMI for waist circum-
ference, potentially weakening our ability to detect excess
visceral fat, thought to be a proximate cause of the compo-
nents of MetS. However, the use of BMI instead of waist
circumference as the obesity component of MetS has been
validated by others (9,10). Third, we did not measure the
duration of MetS or diabetes in this patient population.
Fourth, the size of the group with diabetes without MetS
was small, and therefore, event rates in that subset were
more subject to the play of chance as compared with other
subgroups. Fifth, the vast majority of patients were white
men, limiting translation of our findings to other races and
women. Last, all of the population studied had stable CAD;
therefore, these results apply primarily to such patients, and
caution should be used in generalizing our findings to
patients without CAD.
Conclusions
Detecting MetS appears to be a clinically useful construct to
identify increased risk for death or MI among patients with
stable CAD, even among patients with diabetes. However,
the risk of adverse outcomes observed in patients with MetS
was mediated principally by its component risk factors, with
no additional independent risk imparted by the syndrome
itself. The addition of early PCI to OMT did not reduce the
long-term risk of death or MI in COURAGE patients
regardless of MetS or diabetes status. These observations
undermine the clinical utility of diagnosing patients with
MetS. Nevertheless, CAD patients with diabetes and MetS
are at particularly high risk despite receiving contemporary
aggressive medical therapy, underscoring the need to iden-
tify more effective methods to prevent and treat the indi-
vidual components of the syndrome.
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